Abbvie Inc (ABBV) Stock Price, Quote & News

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 847 932 7900

Website: www.abbvie.com

Address:

1 North Waukegan Road, North Chicago, United States

55X_ROI_Q1_2026 May. 13 at 8:33 PM

$SLS $LLY $ABBV BALLISTIC VERTICALITY INCOMING 2 Stage Launch - 80th Event 150M Shares Will Trade this up to $40 - Top Line Results 600M Shares Will Trade this up to $120 + ... Watch.

0 · Reply

55X_ROI_Q1_2026 May. 13 at 7:15 PM

$SLS The Share Price will continue climbing until the 80th Event PR and then it will Launch - and again We will see ballistic VERTICALITY on the P3 Results. $60 Share /$11B MCap and there will Still be 4X+ More Upside for Black Rock and Vanguard GPS Immunotherapy will treat 100,000 AML Patients Currently in Remission and Generate Billions of Real Revenue That is Worth Every Nickel of $40B to Big Pharma. $LLY $ABBV This Rigged Manipulated Share Price is offering the Investment Opportunity of Our Lifetimes.

0 · Reply

biolover May. 13 at 6:50 PM

$VKTX $ABBV CMO today talks about an obesity interest irrespective of their amylin outcome including “ oral extended half life “

2 · Reply

55X_ROI_Q1_2026 May. 13 at 6:45 PM

$SLS $60 Share/ $11B MCap and there will Still be 4X+ More Upside for Black Rock and Vanguard GPS Immunotherapy is Worth Every Nickel of $40B to Big Pharma. $LLY $ABBV This Rigged Manipulated Share Price is offering the Investment Opportunity of Our Lifetimes.

2 · Reply

55X_ROI_Q1_2026 May. 13 at 6:27 PM

$SLS $60 per Share / $11B MCap and there will Still be 4X+ More Upside for Black Rock and Vanguard GPS Immunotherapy is Worth Every Nickel of $40B to Big Pharma. $LLY $ABBV This Rigged Manipulated Share Price is offering the Investment Opportunity of Our Lifetimes.

0 · Reply

HedgeFollow May. 13 at 3:52 PM

🔍 𝗡𝗲𝘄 13𝗙 𝗥𝗲𝗹𝗲𝗮𝘀𝗲𝗱 🔎 Outstanding Hedge Fund Ensign Peak just filed their 13F for Q1. Most notable position changes: 𝗔𝗱𝗱𝗲𝗱 20-40% 𝗺𝗼𝗿𝗲: $CRM , $GILD , $MRK 𝗗𝗢𝗨𝗕𝗟𝗘𝗗 position: $BSX 𝗥𝗲𝗱𝘂𝗰𝗲𝗱 by 40%: $ABBV Ensign portfolio is up 82% in past 3 years Source: https://hedgefollow.com/funds/Ensign+Peak+Advisors

0 · Reply

CaymanStyleBeef May. 13 at 2:51 PM

$CELH $ABBV starters....start your engines

0 · Reply

Donib11 May. 13 at 2:31 PM

$ABBV I feel this stock does better when market is red. More of a safe play

0 · Reply

NetworkNewsWire May. 13 at 1:19 PM

CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research $OTLC $AMGN $JNJ $ABBV $LNAI https://ibn.fm/v9RPJ

0 · Reply

NetworkNewsWire May. 13 at 1:19 PM

Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities $SURE.CN $SURNF $MRK $ABBV $VKTX $ALT https://ibn.fm/xuvoa

0 · Reply

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

May 8, 2026, 10:00 AM EDT - 5 days ago

AbbVie Transcript: AGM 2026

May 6, 2026, 8:00 AM EDT - 7 days ago

AbbVie to Present at the Bank of America Securities Healthcare Conference

2026-05-05T12:32:52.000Z - 8 days ago

AbbVie presented new data across its gastroenterology portfolio at the 2026 DDW

May 5, 2026, 8:05 AM EDT - 8 days ago

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

IBD

2026-05-04T12:13:35.000Z - 9 days ago

AbbVie price target raised to $236 from $232 at Evercore ISI

May 1, 2026, 3:05 PM EDT - 12 days ago

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

May 1, 2026, 10:03 AM EDT - 12 days ago

Big Pharma M&A set for mega year as patent expiries drive deal urgency

BMY GILD GSK LLY

Apr 30, 2026, 3:00 PM EDT - 13 days ago

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

2026-04-30T18:00:46.000Z - 13 days ago

AbbVie price target raised to $278 from $270 at Morgan Stanley

2026-04-30T13:31:03.000Z - 13 days ago

AbbVie price target raised to $265 from $262 at Canaccord

Apr 30, 2026, 9:00 AM EDT - 13 days ago

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

2026-04-30T10:15:57.000Z - 13 days ago

AbbVie upgraded to Buy at BofA on durable growth

2026-04-30T10:14:18.000Z - 13 days ago

AbbVie upgraded to Buy from Neutral at BofA

2026-04-29T16:41:09.000Z - 14 days ago

AbbVie raises FY26 revenue view to about $67.3B from about $67B

2026-04-29T16:39:58.000Z - 14 days ago

AbbVie sees Q2 adjusted EPS $3.74-$3.78, consensus $3.74

2026-04-29T16:39:07.000Z - 14 days ago

AbbVie sees FY26 adjusted gross margin ‘above 84% of sales’

2026-04-29T13:25:07.000Z - 14 days ago

AbbVie says ‘especially pleased’ with immunology and neuroscience results

Apr 29, 2026, 9:00 AM EDT - 14 days ago

AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 8:32 AM EDT - 14 days ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

2026-04-29T12:15:43.000Z - 14 days ago

AbbVie reports Q1 adjusted EPS $2.65, consensus $2.67

2026-04-29T12:13:45.000Z - 14 days ago

AbbVie raises FY26 adjusted EPS view to $14.08-$14.28 from $13.96-$14.16

Apr 29, 2026, 7:50 AM EDT - 14 days ago

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

Apr 29, 2026, 7:47 AM EDT - 14 days ago

AbbVie Reports First-Quarter 2026 Financial Results

2026-04-29T11:05:22.000Z - 14 days ago

Options Volatility and Implied Earnings Moves Today, April 29, 2026

AMZN F GOOG GOOGL META MSFT QCOM

Apr 28, 2026, 8:00 AM EDT - 15 days ago

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

Apr 28, 2026, 7:00 AM EDT - 15 days ago

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

Apr 27, 2026, 8:05 AM EDT - 16 days ago

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

Apr 23, 2026, 4:19 PM EDT - 20 days ago

US FDA declines to approve AbbVie's wrinkle treatment

Apr 23, 2026, 4:05 PM EDT - 20 days ago

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

Apr 22, 2026, 12:59 PM EDT - 21 days ago

AbbVie to build $1.4 billion manufacturing campus in North Carolina

Apr 22, 2026, 12:02 PM EDT - 21 days ago

AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

Apr 20, 2026, 2:30 AM EDT - 23 days ago

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Apr 14, 2026, 8:50 AM EDT - 4 weeks ago

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Apr 13, 2026, 2:24 AM EDT - 4 weeks ago

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

Apr 12, 2026, 7:15 AM EDT - 4 weeks ago

AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

Apr 8, 2026, 1:38 PM EDT - 5 weeks ago

AbbVie files lawsuit to address 'outdated' drug discount eligibility program

Apr 8, 2026, 8:00 AM EDT - 5 weeks ago

BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year

Apr 7, 2026, 9:53 AM EDT - 5 weeks ago

The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it.

Apr 7, 2026, 9:00 AM EDT - 5 weeks ago

Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin

Apr 3, 2026, 11:08 AM EDT - 5 weeks ago

Swiss industry body says US tariffs on pharmaceuticals will harm patients

AMGN AZN BMY MRK NVO

Apr 2, 2026, 5:34 PM EDT - 5 weeks ago

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

AZN NVO AMGN BMY MRK

Apr 2, 2026, 5:33 PM EDT - 5 weeks ago

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

AMGN AZN BMY MRK NVO

Apr 2, 2026, 3:29 PM EDT - 5 weeks ago

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

AZN NVO AMGN BMY MRK

Apr 2, 2026, 2:59 PM EDT - 5 weeks ago

Global pharma companies that have publicly announced Trump drug pricing agreements

AMGN AZN BMY MRK

Mar 31, 2026, 8:05 AM EDT - 6 weeks ago

Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®

Mar 31, 2026, 8:00 AM EDT - 6 weeks ago

AbbVie to Host First-Quarter 2026 Earnings Conference Call

Mar 27, 2026, 10:00 AM EDT - 6 weeks ago

AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

Mar 24, 2026, 8:00 AM EDT - 7 weeks ago

AbbVie Named Official Pharmaceutical Partner of Major League Baseball

Mar 20, 2026, 12:11 PM EDT - 7 weeks ago

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

AMRX NVS OGN

Mar 19, 2026, 9:26 AM EDT - 7 weeks ago

Buy Or Fear AbbVie Stock At $210?

Mar 19, 2026, 3:00 AM EDT - 7 weeks ago

Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

Mar 18, 2026, 2:23 PM EDT - 2 months ago

TrumpRx lists many medicines at prices higher than paid in UK

AMGN AZN BMY GILD GSK JNJ LLY

Mar 17, 2026, 2:32 PM EDT - 2 months ago

Big drugmakers must face US overcharge claims on medications for low-income patients

AZN NVS SNY

Mar 13, 2026, 9:00 AM EDT - 2 months ago

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

Mar 10, 2026, 11:20 AM EDT - 2 months ago

AbbVie Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 8:00 AM EDT - 2 months ago

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

Mar 3, 2026, 11:10 AM EST - 2 months ago

AbbVie Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 8:00 AM EST - 2 months ago

AbbVie to Present at the Leerink Partners Global Healthcare Conference

Mar 2, 2026, 8:30 AM EST - 2 months ago

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

Feb 24, 2026, 8:00 AM EST - 2 months ago

AbbVie to Present at the TD Cowen 46th Annual Health Care Conference

Feb 23, 2026, 12:03 PM EST - 2 months ago

AbbVie to invest $380 million to expand US manufacturing in Illinois

Feb 23, 2026, 11:00 AM EST - 2 months ago

AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States

Feb 20, 2026, 2:00 AM EST - 2 months ago

U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

Feb 19, 2026, 9:37 AM EST - 2 months ago

AbbVie Declares Quarterly Dividend

Feb 13, 2026, 10:00 AM EST - 3 months ago

AbbVie Transcript: Piper Sandler Virtual Novel Targets in Immunology Symposium

Feb 11, 2026, 6:49 PM EST - 3 months ago

AbbVie sues US health agency over Botox price controls

Feb 11, 2026, 5:13 PM EST - 3 months ago

Abbvie sues US health agency over Botox

Feb 4, 2026, 9:00 AM EST - 3 months ago

AbbVie Earnings Call Transcript: Q4 2025

Feb 4, 2026, 8:34 AM EST - 3 months ago

AbbVie Revenue Rises on Immunology Growth

55X_ROI_Q1_2026 May. 13 at 8:33 PM

$SLS $LLY $ABBV BALLISTIC VERTICALITY INCOMING 2 Stage Launch - 80th Event 150M Shares Will Trade this up to $40 - Top Line Results 600M Shares Will Trade this up to $120 + ... Watch.

0 · Reply

55X_ROI_Q1_2026 May. 13 at 7:15 PM

0 · Reply

biolover May. 13 at 6:50 PM

$VKTX $ABBV CMO today talks about an obesity interest irrespective of their amylin outcome including “ oral extended half life “

2 · Reply

55X_ROI_Q1_2026 May. 13 at 6:45 PM

2 · Reply

55X_ROI_Q1_2026 May. 13 at 6:27 PM

0 · Reply

HedgeFollow May. 13 at 3:52 PM

0 · Reply

CaymanStyleBeef May. 13 at 2:51 PM

$CELH $ABBV starters....start your engines

0 · Reply

Donib11 May. 13 at 2:31 PM

$ABBV I feel this stock does better when market is red. More of a safe play

0 · Reply

NetworkNewsWire May. 13 at 1:19 PM

CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research $OTLC $AMGN $JNJ $ABBV $LNAI https://ibn.fm/v9RPJ

0 · Reply

NetworkNewsWire May. 13 at 1:19 PM

Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities $SURE.CN $SURNF $MRK $ABBV $VKTX $ALT https://ibn.fm/xuvoa

0 · Reply

55X_ROI_Q1_2026 May. 13 at 1:10 PM

$SLS should be +100% today - and that is just a starter. GPS is worth a Full $40B + to Big Pharma. A revolutionary, AML Remission Maintenance Immunotherapy, that extends Survival 3X 4X+ with low to No Side Effects, and an Unlimited dosing regime. Gps will Set Records for Patient Uptake rates. FDA/EU Orphan / Fast Track / Rare Priority Review - BLA NOW BEING Prepared. IP Rights Into 2037 - $ABBV $BMY $MRK all Know Gps is the only reason we are seeing Miraculous all Pooled Surivival. BAT/ AZA+VEN RECENTLY FAILED 3 Large Phase 3 Trials for AML Remission Maintenance. it is Not complicated.

0 · Reply

Bio_buyout May. 13 at 10:31 AM

$SLS $PFE $MRK $ABBV #2 Trending is all of Stocktwists

0 · Reply

maikl_211 May. 13 at 7:31 AM

$DJT MAGA Supporters CRUSHED After Shattering Trump Mobile Truth Surfaces He sells his Chinese goods to his foolish followers. $COST $NFLX $BAC $ABBV https://www.youtube.com/watch?v=O-ynb-Cin9s

2 · Reply

focafoca99 May. 12 at 9:50 PM

$ABBV elected its Class II directors and ratified EY as auditor at its 2026 annual meeting. https://www.rapidticker.com/news/abbv-sec-filing-8-k-5cb052

0 · Reply

55X_ROI_Q1_2026 May. 12 at 9:02 PM

$SLS $ABBV Sub $10 is C.A.P. PSA: for anyone who doesn't know. Azacitidine + Venetoclax, the BAT- Best Available Treatment for Control Arm Patients - Recently FAILED 3 Large Phase 3 AML Trials conducted by ABBV. VIALE-M - AML First Remission (CR1) Maintenance Trial - FAILED VIALE-T - AML Post Transplant Maintenance Trial - Failed ABBV Knows its Gps / Doing what its done in all Previous Trials, Prevent Relapse and Extend Survival - including in 2 Previous Phase 2 AML Remission Maintenance Trials. Gps Immunotherapy is worth $40B to Big Pharma. - I've been here a while and done much dd if anyone wants to get up to speed, scroll my posts.

0 · Reply

55X_ROI_Q1_2026 May. 12 at 8:51 PM

$SLS @onthebalance How many repositioners just Got Left Off the Boat?? LOL GPS is worth a Full $40B + to Big Pharma. A revolutionary, AML Remission Maintenance Immunotherapy, that extends Survival 3X 4X+ with low to No Side Effects, and an Unlimited dosing regime. Gps will Set Records for Patient Uptake rates. FDA/EU Orphan / Fast Track / Rare Priority Review - BLA NOW BEING Prepared. IP Rights Into 2037 - $ABBV $BMY $MRK all Know Gps is the only reason we are seeing Miraculous all Pooled Surivival. BAT/ AZA+VEN RECENTLY FAILED 3 Large Phase 3 Trials for AML Remission Maintenance. it is Not complicated.

0 · Reply